Nanoviricides (Nanoviricides) Net Change in Cash

: $-6.20 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Nanoviricides's Net Change in Cash for the three months ended in Dec. 2023 was $-1.72 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.20 Mil.

Nanoviricides Net Change in Cash Historical Data

The historical data trend for Nanoviricides's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Change in Cash

-4.53

11.15

6.81

-6.45

-5.92

Nanoviricides Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash																-1.47	-1.80	-1.50	-1.18	-1.72

Nanoviricides Net Change in Cash Calculation

Nanoviricides's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-5.67	+	-0.152	+	-0.095	+	0
	=	-5.92

Nanoviricides's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -1.719 + -0.005 + 0 + 0

= -1.72

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoviricides Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Nanoviricides's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoviricides (Nanoviricides) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Net Change in Cash

Comparable Companies

LABP APM NHWK CUBT MBIO AZTR LEXX PHGE VIRI AMTI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY

Traded in Other Exchanges

NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Executives

Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484

Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484

Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516

Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017

Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides (Nanoviricides) Headlines

From GuruFocus

NanoViricides to Present at the Biotech Showcase in San Fransisco
By ACCESSWIRE • 01-04-2024

Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
By ACCESSWIRE • 07-11-2023

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
By ACN Newswire • 06-29-2023

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
By ACCESSWIRE • 07-06-2023

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
By ACCESSWIRE ACCESSWIRE • 08-04-2022

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
By ACCESSWIRE • 11-28-2023

NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
By ACCESSWIRE ACCESSWIRE • 02-15-2023

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
By ACCESSWIRE • 06-29-2023

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
By ACCESSWIRE ACCESSWIRE • 11-16-2021

NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
By ACCESSWIRE ACCESSWIRE • 05-16-2022

Makarand Jawadakar	director	C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day	director	C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk	director	C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan	director, 10 percent owner, officer: President	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni	director	C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas	officer: Chief Financial Officer	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour	director, 10 percent owner	666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc.	10 percent owner	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516